Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Completed 5Withdrawn 1Terminated 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 123Breast Neoplasms 103Neoplasms 100Leukemia, Myeloid, Acute 88Melanoma 86Multiple Myeloma 81Neoplasm Metastasis 80Recurrence 68Ovarian Neoplasms 65Prostatic Neoplasms 59Lymphoma 59Colorectal Neoplasms 58Lymphoma, Non-Hodgkin 55Leukemia 55Pancreatic Neoplasms 50Lung Neoplasms 48Myelodysplastic Syndromes 42Leukemia, Lymphocytic, Chronic, B-Cell 42Carcinoma, Renal Cell 39Squamous Cell Carcinoma of Head and Neck 38Precursor Cell Lymphoblastic Leukemia-Lymphoma 38Glioblastoma 35Lymphoma, Large B-Cell, Diffuse 34Carcinoma, Hepatocellular 33Triple Negative Breast Neoplasms 32Stomach Neoplasms 29Small Cell Lung Carcinoma 27Lymphoma, Follicular 27Brain Neoplasms 26Lymphoma, Mantle-Cell 25

Interventions

Rituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Terminated × Central Nervous System Diseases × Clear all
NCT01596127 2018-05-24

Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System

M.D. Anderson Cancer Center

Phase 1/2 Terminated
4 enrolled 7 charts
CNSOther hematologic neoplasm

Central Nervous System Diseases, Leukemia, Meningeal Neoplasms, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡